Question Title

* 1. EJ is a 66-year-old male with newly diagnosed CLL (Rai stage III, complex karyotype, 5 cm cervical lymphadenopathy). PMH includes hypothyroidism and depression. What is the best treatment option?

Question Title

* 2. One of your CLL patients is currently relapsing on front-line ibrutinib. A C481S BTK mutation has also been confirmed. What is the best next step?

Question Title

* 3. JM began ibrutinib 2 months ago for newly diagnosed CLL. He experienced severe arthralgia, which improved after a short course of corticosteroids. Unfortunately, the arthralgia recurred and persisted even after reducing the dose of ibrutinib. What is the best course of action?

Question Title

* 4. JJ is a 60-year-old male with newly diagnosed, high-risk CLL requiring treatment. His past medical history is significant for unprovoked venous thromboembolism requiring prolonged anticoagulation. Which of the following statements is true regarding initiation of ibrutinib in this patient?

Question Title

* 5. EB is a 72-year-old female with relapsed CLL who initiated acalabrutinib 100 mg PO twice daily 2 weeks ago. She presents to clinic with complaints of daily headaches. Which of the following would be the best response?

Question Title

* 6. What clinical questions do you have about BTK inhibitors in CLL (including management in the era of COVID-19)?

T